This explains why certain drugs require remarkably higher oral doses than intravenous administration, while others are administered through sublingual, transdermal, rectal, or parenteral routes to bypass first-pass metabolism altogether
News provided by Eli Lilly and Company Jul 23, 2026, 06:45 ET In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist
Ozempic is an injectable medication approved for treating type 2 diabetes
It has a long half-life period and is injected once a week
A clinician from the Lion MD network reviews the submission and determines whether GLP-1 therapy is medically appropriate for that specific patient
doi: 10.1056/NEJMoa1509225 62 FonsecaVAAlvarado-RuizRRaccahDBokaGMiossecPGerichJEet al
.png)
